StockData
IRIDEX Corp logo

IRIDEX Corp (IRIX) stock

IRIXNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends January 3
Financials through Q3 FY2026, quarter ended Oct 3, 2026Last filing: 10-Q on Nov 17, 2026Score 8/30
$0.70+0.01 (+1.72%)

Close on Nov 17, 2026Market cap $12.29MP/E –Yield –

Earnings

Iridex's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 11, 2026
Q3 FY2026 · estimated, after the close
Revenue, Q2 FY2026
$12.60M
-7.4% on a year earlier
EPS, Q2 FY2026
-$0.07
-$0.06 a year earlier
Latest guidance
Reaffirmed
Aug 18, 2026 · 2 items

Quarterly results

Revenue and earnings per share from each of Iridex's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 27, 2026Nov 11, 2026Expected––––
Q2 FY2026ended Jul 4, 2026Aug 18, 2026after the close$12.60M-7.4%-$0.07Release
Q1 FY2026ended Apr 4, 2026May 19, 2026after the close$11.80M-0.8%-$0.03Release
Q4 FY2025ended Jan 3, 2026Mar 26, 2026after the close$14.70M+15.7%-$0.01Release
Q3 FY2025ended Sep 27, 2025Nov 12, 2025after the close$12.50M+7.8%-$0.09Release
Q2 FY2025ended Jun 28, 2025Aug 12, 2025after the close$13.60M+7.9%-$0.06Release
Q1 FY2025ended Mar 29, 2025May 13, 2025after the close$11.90M+0.8%-$0.10Release
Q4 FY2024ended Dec 28, 2024Mar 27, 2025after the close$12.70M–-$0.05Release
Q3 FY2024ended Sep 28, 2024Nov 12, 2024after the close$11.60M-10.1%–Release
Q2 FY2024ended Jun 29, 2024Aug 8, 2024after the close$12.60M-2.3%-$0.16Release
Q1 FY2024ended Mar 30, 2024May 14, 2024after the close$11.80M-13.9%-$0.21Release
Q3 FY2023ended Sep 30, 2023Nov 14, 2023after the close$12.90M-11.6%-$0.11Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Iridex's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
annual revenueFY2026$51.00M – $53.00M$51.00M – $53.00MReaffirmedAug 18, 2026
growthnon-GAAPFY2026+1% – +5%–NewMar 26, 2026
revenueFY2026$51.00M – $53.00M–NewMar 26, 2026
adjusted operating expensesnon-GAAPFY2026$19.00M – $19.50M$19.00M – $19.50MReaffirmedAug 18, 2026
adjusted operating expensesnon-GAAPFY2026$19.00M – $19.50M–NewMar 26, 2026

Guidance vs results

The last range Iridex gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
Q4 FY2021Revenue$15.10M – $15.30M$15.30MWithin range

Guidance history

Every forecast Iridex put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Aug 18, 2026adjusted operating expensesFY2026$19.00M – $19.50MReaffirmed
Aug 18, 2026annual revenueFY2026$51.00M – $53.00MReaffirmed
May 19, 2026adjusted operating expensesFY2026$19.00M – $19.50MNew
May 19, 2026annual revenueFY2026$51.00M – $53.00MNew
Mar 26, 2026adjusted operating expensesFY2026$19.00M – $19.50MNew
Mar 26, 2026growthFY2026+1% – +5%New
Mar 26, 2026revenueFY2026$51.00M – $53.00MNew
Aug 10, 2023Cyclo G6 probe salesFY202361,000 – 63,000Raised
Aug 10, 2023Cyclo G6 systems installed base expansionFY2023210 – 230Lowered
Aug 10, 2023Total revenueFY2023$55.00M – $57.00MLowered
May 11, 2023Cyclo G6 probe salesFY202365,000 – 67,000Raised
May 11, 2023Cyclo G6 systems installed baseFY2023225 – 250Lowered
May 11, 2023Total revenueFY2023$57.00M – $59.00MReaffirmed
Mar 9, 2023Cyclo G6 probe salesFY202365,000 – 67,000New
Mar 9, 2023Cyclo G6 systems installed baseFY2023225 – 250Lowered
Mar 9, 2023Total revenueFY2023$57.00M – $59.00MNew
Nov 10, 2022Glaucoma Laser System installed base to expandFY2022225 – 250Reaffirmed
Nov 10, 2022Cyclo G6 probe unit salesFY202260,000Raised
Nov 10, 2022total revenueFY2022$56.00M – $58.00MReaffirmed
Aug 15, 2022Cyclo G6 probe salesFY202261,000 – 63,000Raised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Iridex filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Update
  4. Results
  5. Results
  6. Results
  7. Update
  8. Results
  9. News
  10. Results
  11. Results
  12. Results
  13. Results
  14. News
  15. Results

See a number that looks wrong?